LoadingLoadingLoadingNet selling: insiders sold $1.2M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full results8 funds hold a position and insiders have been net selling.
Buys/Adds (2)
Two Sigma
$45.1M
added
Millennium
$26.8M
bought
Sells/Trims (1)
D.E. Shaw
$39.1M
trimmed
Top-trader positions in ARWR could not be loaded.
Hyperliquid positioning - not every stock is covered
Last report
Aug 4, 2026
Period ending
Jun 30, 2026
Earnings per share
-$1.23 expected
Revenue
Financial statements: Alpha Vantage
Estimates as of Oct 24, 2026
EPS expected
-$3.00 to -$0.35
Revenue expected
15 analysts
Last 30 days
Analysts cutting estimates
Estimate drift
Change in 30 days
| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / income | Surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 4, 2026 | -$1.36 / -$1.23Yahoo Finance | -10.35% miss | $75.3M No estimate | Unavailable |
| Mar 31, 2026 | May 7, 2026 | -$0.93 / -$1.11Yahoo Finance | +15.98% beat | $73.7M No estimate | Unavailable |
| Dec 31, 2025 | Feb 5, 2026 | $0.22 / -$0.37Yahoo Finance | +$0.59 beat | $264.0M No estimate | Unavailable |
| Sep 30, 2025 | Nov 25, 2025 | -$0.18 / -$0.16Yahoo Finance | -14.45% miss | $256.5M No estimate | Unavailable |
| Jun 30, 2025 | Aug 7, 2025 | -$1.26 / -$0.94Alpha Vantage | -34.04% miss | $27.8M No estimate | Unavailable |
| Mar 31, 2025 | May 12, 2025 | $2.75 / -$0.46Alpha Vantage | +$3.21 beat | $542.7M No estimate | Unavailable |
| Dec 31, 2024 | Feb 10, 2025 | -$1.39 / -$0.72Alpha Vantage | -93.06% miss | $2.5M No estimate | Unavailable |
| Sep 30, 2024 | Nov 26, 2024 | -$1.37 / -$0.92Alpha Vantage | -48.59% miss | $23.6M No estimate | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue and income use company releases, SEC filings, Alpha Vantage or Yahoo Finance. Non-USD revenue carries its currency code. Comparisons require a paired release estimate.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $256.5M | $264.0M | $73.7M | $75.3M |
| Cost of what it sold | $6.4M | $6.4M | $6.4M | — |
| Gross profit | $256.5M | $264.0M | $73.7M | $75.3M |
| What it spent | ||||
| Research and development | $174.7M | $177.2M | $173.3M | $198.2M |
| Sales and admin | $37.2M | $45.5M | $41.2M | $46.6M |
| Total operating expenses | $212.4M | $223.2M | $215.0M | $245.3M |
| What was left | ||||
| Operating profit | $44.1M | $40.8M | -$141.3M | -$170.1M |
| Interest on debt | $21.7M | $22.5M | $23.8M | $24.6M |
| Profit before tax | $36.1M | $28.3M | -$137.6M | -$178.9M |
| Tax | $20.0M | $29.0K | $7.0K | $11.0K |
| Net profit | -$23.8M | $30.8M | -$132.7M | -$194.3M |
| EBITDA | $64.2M | $57.2M | -$107.4M | -$147.7M |
This stock is under pressure.
Trend
Under pressure
0 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
Arrowhead Pharmaceuticals, Inc. (0HI3.IL) stock price, news, quote and history
BullishOct 18The future of RNAi with Arrowhead’s Chris Anzalone on The BioCentury Show
BullishOct 17Arrowhead Pharmaceuticals Advances Alzheimer's Drug Push With Promising Early Clinical Results
BullishOct 16Piper Sandler Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $126
BullishOct 16UBS Adjusts Price Target on Arrowhead Pharmaceuticals to $109 From $63, Maintains Buy Rating
BullishOct 16Arrowhead Pharmaceuticals Reports Up to 73% CSF Tau Reduction in Early ARO-MAPT Study
BullishOct 14Arrowhead Pharmaceuticals Advances Alzheimer's Drug Push With Promising Early Clinical Results
Leans bullishOct 14Arrowhead stock gains on trial data for Alzheimer’s drug (ARWR)
BullishOct 14